Source comparison
CJC-1295 vs Modified GHRH: Pharmacokinetic Comparison
CJC-1295 with DAC 6–8 days 7–9 days post-injection Once or twice weekly Sustained GH elevation models requiring minimal dosing intervention Best option for long-duration studies. Albumin binding creates stable plasma levels without daily administration CJC-129
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC
- 6–8 days
- 7–9 days post-injection
- Once or twice weekly
- Sustained GH elevation models requiring minimal dosing intervention
- Best option for long-duration studies. Albumin binding creates stable plasma levels without daily administration
- CJC-1295 no DAC (Modified GRF 1-29)
- 30 minutes
- 2–4 hours
- 2–3 times daily
- Acute GH release studies, meal-timed protocols
- Suitable for pulsatile GH research mimicking endogenous secretion. Short half-life allows precise temporal control
- Tesamorelin
- 26–38 minutes
- 3–6 hours
- Daily subcutaneous
- HIV-associated lipodystrophy research, visceral fat reduction models
- FDA-approved GHRH analogue with clinical trial data. Used when regulatory approval matters more than convenience
- Native GHRH (1-44)
- <7 minutes
- 30–90 minutes
- Continuous infusion or hourly bolus
- Mechanistic studies of pituitary GH secretion
- Gold standard for acute pituitary function testing. Impractical for extended studies
- Sermorelin
- 8–12 minutes
- 2–3 hours
- Paediatric GH deficiency models, diagnostic testing
- Longer than native GHRH but still requires frequent dosing. Historical use in clinical diagnostics
- The half-life difference is the defining constraint. Research protocols requiring daily blood sampling, tissue biopsies, or metabolic assessments over 1–2 weeks become logistically unmanageable with peptides requiring multiple daily injections. CJC-1295 with DAC reduces dosing burden while maintaining the GH-elevated state continuously. Critical for studies where repeated handling or injection stress could confound results.